Group 1 - The board of directors of Yuanda Holdings approved the establishment of a traditional Chinese medicine (TCM) seed industry company, with a unanimous vote of 14 in favor [1] - The company will invest 81.25 million yuan through its wholly-owned subsidiary, Yuanda Biological Agriculture Co., Ltd., in collaboration with Gansu Hebo Long Medicine Technology Co., Ltd. and Professor Shao Baoping's team [1] - The new company will focus on three core areas: the creation of quality resources and biobreeding technology for TCM materials like Codonopsis pilosula and Astragalus membranaceus, the development of soilless seedling breeding technology, and the deep development and commercialization of TCM health products [1] Group 2 - Codonopsis pilosula is a key TCM material known for its ability to enhance energy and nourish the lungs, with a market sales forecast of approximately 8.5 billion yuan in 2024, and a total market size of 14.86 billion yuan when including the entire industry chain [2] - The market for Codonopsis pilosula is expected to grow at an annual rate of 9% to 12%, potentially exceeding 13.5 billion to 28 billion yuan by 2030 [2] - Astragalus membranaceus is recognized for its multiple health benefits, with a projected market sales of around 18.5 billion yuan in 2024, and a total market size of 30 billion yuan by 2030, growing at an annual rate of 8% to 10% [3] Group 3 - Yuanda Biological Agriculture Co., Ltd. has established a comprehensive strategic development plan since 2021, focusing on core agricultural inputs such as biopesticides and biofertilizers [3] - The company aims to provide integrated support for the production of high-end functional health foods, covering the entire process from quality resource creation to standard control in processing [3] - The collaboration represents the first industrial chain layout in the TCM field for Yuanda Holdings, leveraging biotechnological innovation to upgrade the traditional TCM industry [4]